secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2026-05-12T20:10:17+00:00
Accession:  0001193125-26-219422
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q1 2026: $5.8M KOMZIFTI net revenue in first full commercial quarter; cash $580.8M
--------------------------------------------------------------------------------

- Net product revenue $5.8M from KOMZIFTI in first full commercial quarter; 85 new patient starts, 157 total prescriptions.
- Net loss $73.3M (Q1 2025: $57.4M); R&D expense $65.3M, SG&A $31.6M on commercialization investments.
- Cash $580.8M plus $180M anticipated Kyowa Kirin payments expected to fund ziftomenib program through 2028.
- Payer coverage >93% across >12M lives; early adoption includes repeat use, switching from other menin inhibitors.
- Multiple 2026 catalysts: EHA updated KOMET-007 data, ASCO darlifarnib/adagrasib data, KOMET-008 preliminary data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/0001193125-26-219422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/kura-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer